|
Would you like to pinpoint the signaling pathways regulated by your gene product
or compound, in cell types not amenable to high efficiency transfection? If so,
consider Cignal Finder Lenti Reporter Arrays, the first commercial products that
enable a comprehensive analysis of multiple pathways (up-to ten) in
difficult-to-transfect cells. This system utilizes a unique combination of
transcription factor reporter technology coupled with lentiviral delivery power.
Why Cignal Finder Lenti 10-Pathway Reporter Arrays?
- Comprehesive biology: Profile changes in the activities of ten
signaling pathways relevant to a specific biological process
- Transduce any cell type:
Transduce virtually any cell type, including non-dividing cells, stem cells,
and differentiated cells
- Ready to transduce:
Lentiviral vectors arrive as transduction-ready lentiviral particles,
eliminating any need to construct and amplify lentivirus in your laboratory
Which ten pathways? See the Cignal Finder Array pathway lists
- Cancer Reporter Array
| Tube/Column |
Pathway |
| 1 |
Wnt |
| 2 |
Notch |
| 3 |
p53/DNA Damage |
| 4 |
TGFβ |
| 5 |
Cell cycle/pRb-E2F |
| 6 |
NFκB |
| 7 |
Myc |
| 8 |
Hypoxia |
| 9 |
MAPK/ERK |
| 10 |
MAPK/JNK |
| 11 |
Cignal negative control |
| 12 |
Cignal positive control |
|
- Immune Response Reporter Array
| Tube/Column |
Pathway |
| 1 |
NFκB |
| 2 |
PKC/Ca++ |
| 3 |
Type 1 Interferon |
| 4 |
Gamma Interferon |
| 5 |
MAPK/ERK |
| 6 |
MAPK/JNK |
| 7 |
TGFβ |
| 8 |
cAMP/PKA |
| 9 |
C/EBP |
| 10 |
Glucocorticoid Receptor |
| 11 |
Cignal negative control |
| 12 |
Cignal positive control |
|
- Development Reporter Array
| Tube/Column |
Pathway |
| 1 |
Notch |
| 2 |
Wnt |
| 3 |
Myc |
| 4 |
NFκB |
| 5 |
TGFβ |
| 6 |
Cell cycle/pRb-E2F |
| 7 |
C/EBP |
| 8 |
cAMP/PKA |
| 9 |
MAPK/ERK |
| 10 |
MAPK/JNK |
| 11 |
Cignal negative control |
| 12 |
Cignal positive control |
|
- Toxicity Reporter Array
| Tube/Column |
Pathway |
| 1 |
p53/DNA Damage |
| 2 |
Hyoxia |
| 3 |
NFκB |
| 4 |
Glucocorticoid Receptor |
| 5 |
Cell cycle/pRb-E2F |
| 6 |
MAPK/ERK |
| 7 |
MAPK/JNK |
| 8 |
PKC/Ca++ |
| 9 |
TGF |
| 10 |
Myc |
| 11 |
Cignal negative control |
| 12 |
Cignal positive control |
|
The Cignal Finder 10-Pathway Reporter Arrays are ideally suited for discovering:
- siRNA/shRNA/miRNA phenotypes
- Biological responses to chemical compounds
- Mechanisms of action of proteins, peptides, and ligands
Available Cignal Finder 10-Pathway Reporter Arrays (luciferase)
How It Works
Each Lenti Reporter Array includes 10 Cignal Lenti Pathway Reporters and two
controls. All reporters and controls are delivered as transduction-ready
lentiviral particles (250µl at 1X107 transducing units/ml). All reporter assays
utilize firefly luciferase reporter gene technology.
Firefly luciferase results are calculated for each transduced culture. The change
in the activity of each signaling pathway is determined by comparing the
normalized luciferase activities of the reporter in treated versus untreated
cells.
The identically treated negative control expresses firefly luciferase under
the control of a minimal promoter and serves as a pathway specificity control.
The positive control is a valuable reagent for optimizing your transduction
conditions, by monitoring GFP expression.
The Cignal Lenti Reporters are ready for transduction right out of the box.
There is no need to generate or propagate lentivirus in your laboratory. These
vectors are extremely useful for transient transduction studies in difficult to
transfect cells or for pathway sensor cell line generation.
Transient Pathway Regulation Studies in Difficult to Transfect Cell Lines:
Target cells are transduced with the Cignal Lenti Pathway Reporter. The cells
are typically cultured for 24 to 48 hours to insure lentivirus integration. The
cultures are then treated with the biological agents of interest (siRNA, shRNA,
chemical compound, viral expression vector, protein, peptide). Reporter assays
(firefly luciferase or GFP) are carried out 18 to 36 hours post-treatment,
depending upon the treatment conditions.
Pathway Sensor Cell Line Generation: Target cells are transduced with
the Cignal Lenti Pathway Reporter. Following transduction, the cells are
cultured under puromycin selection to generate a homogenous population of
transduced cells. If necessary, single cell cloning may be carried out in order
to isolate a clonal pathway sensor cell line. These pathway sensor cell lines
serve as a valuable cell-based assay platform, for subsequent screening and
mechanism of action studies.
Simple Procedure:
- Transduce Cignal Lenti Reporters into target cells
- Treat with nucleic acid, protein, peptide, or small molecule of interest
- Perform reporter quantitation using firefly luciferase activity assay
Biosafety Features
The Cignal Lenti Reporters are ready-to-transduce, replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles. The Cignal Lentiviral particles are safe to use. It is
recommended that they be treated as Risk Group Level 2 (RGL-2) organisms. Follow
all published RGL-2 guidelines for handling and waste decontamination. Details
on the requirements for creating a BSL-2 work environment are available in the
U.S. Department of Health and Human Services publication Biosafety in
Microbiological and Biomedical Laboratories, 4th edition.
The biosafety features engineered into these vectors include:
-
A deletion in the promoter/enhancer region of the U3 portion
of 3'LTR ensures self-inactivation of the lentiviral construct after
transduction and integration into the genomic DNA of target cells.
- The Cignal Lentiviral vector and plasmids expressing packaging proteins
contain no significant areas of homology, thereby minimizing any chance for
recombination.
-
None of the HIV-1 genes (gag, pol, rev) will be expressed in
transduced cells, as they are expressed from packaging plasmids lacking
packaging signal. Therefore, the lentiviral particles that are generated are
replication-incompetent
-
No virulence genes ( vpr, vif, vpu and nef) are present in
the Cignal Lentiviral vector.
| Feature |
Function |
| RSV-5' LTR; Hybrid Rous sarcoma Virus (RSV)
enhancer/promoter-U5 long terminal repeat |
Permits viral packaging and reverse
transcription of viral mRNA |
| Psi; Packaging signal |
Allow viral packaging |
| RRE; Rev response element |
Involved in packaging of viral transcript |
| cppt; Central polypurine tract |
Involved in nuclear translocation and
integration of transduced viral genome |
| Reporter gene (firefly luciferase or GFP) |
Allow quantification of transcription |
| hPGK; human phosphoglycerate kinase
eukaryotic promoter |
Permits high-level expression of the
mammalian selection marker (puromycin) |
| PuroR; puromycin resistance gene |
Can be used for mammalian selection |
| SIN/3'LTR; 3' self inactivating long terminal
repeat |
Modified 3'LTR that allows viral packaging
but self inactivates the 5'LTR for biosafety purpose. The element also
contains a polyadenylation signal for efficient transcription
termination |
| f1 ori; f1 origin of replication |
Allows episomal replication of plasmid in
eukaryotic cells
|
| AmpR; ampicillin resistance gene |
Allows selection of the plasmid in E.coli |
| TRE; Transcription response element |
Permits regulation of reporter gene
expression by a specific transcription factor |
| TATA box |
Act as an minimal promoter |
Back to top
|
 |
|